Morgan Stanley Sticks to Their Buy Rating for CSL (CMXHF)

Tip Ranks
2025.12.03 23:07
portai
I'm PortAI, I can summarize articles.

Morgan Stanley analyst David Bailey maintained a Buy rating on CSL, setting a price target of A$256.00. Bailey, a 4-star analyst with a 10.1% average return, focuses on the Healthcare sector. The general analyst consensus for CSL is a Strong Buy with a $159.89 average price target.

Morgan Stanley analyst David Bailey maintained a Buy rating on CSL today and set a price target of A$256.00.

TipRanks Cyber Monday Sale

  • Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
  • Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

According to TipRanks, Bailey is a 4-star analyst with an average return of 10.1% and a 40.54% success rate. Bailey covers the Healthcare sector, focusing on stocks such as CSL, Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh, and Resmed.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for CSL with a $159.89 average price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer